Company news

Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A (SSE:688266) news

Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases on 6ix. Latest, Sep 8, 2026: "Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement…

Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A (SSE:688266) news

Press releases & updates

"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of the Supplemental New Drug Application for Human Thyrotropin Beta for Injection

"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Semi-annual Report for 2026

"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata

Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary Endpoint

Announcement on Change of Accounting Policies

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Announcement on Results of Shareholding Reduction by Shareholder, Director and Senior Management Member

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Announcement on Changes of Core Technical Personnel

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Shareholding Reduction Plan of Shareholders, Directors and Senior Management Members

Earnings Preannouncement for 2025

Announcement on Actual Controller Renewing the Concerted Action Agreement

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Platinum-Containing Chemotherapy Regimen

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZGGS18 and Injectable ZG005 with Chemotherapy Regimen

Announcement on Voluntary Disclosure of the Approval for Market Launch of Recombinant Human Thyrotropin β for Injection

Announcement on Conclusion of a Global Strategic Cooperation and License Option Agreement with AbbVie Regarding the Development and Commercialization Rights of ZG006

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Voluntary Disclosure of Inclusion of Gecacitinib Hydrochloride Tablets in the 2025 National Medical Insurance Drug Catalog

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 Presented at the 2025 European Society for Medical Oncology Asian Annual Meeting (ESMOAsia)

Announcement on Voluntary Disclosure of the Inclusion of ZG006 for Injection for the Treatment of Advanced Neuroendocrine Carcinoma in the Publicity List for Breakthrough Therapy Designation

泽璟制药关于自愿披露注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗（依托泊苷/卡铂）联用获得药物临床试验批准通知书的公告

Announcement on Voluntary Disclosure of FDA Orphan Drug Designation for Injectable ZG006 in the Treatment of Neuroendocrine Cancer

Announcement on Resolutions of the 3rd Meeting of the 4th Board of Directors

Announcement on Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Combination of ZG006 for Injection with Etoposide and Cisplatin

Report for Q3 2025

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Reaching the Primary Efficacy Endpoint

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 and ZG005 Presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZGGS34 for Injection

Announcement on Voluntary Disclosure of the Conduct of Key Clinical Trials for ZG006 for Injection and Completion of the Enrollment of the First Subject

Announcement on Change of Sponsor Representative for Continuous Supervision

Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 and ZG005 Released at the 28the Chinese Society of Clinical Oncology (CSCO) Annual Meeting

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

Announcement on Voluntary Disclosure of Obtaining FDA Approval for the Clinical Trial of ZG005 for Injection In Combination with ZGGS18 for Injection

Announcement on Using Self-owned Funds to Pay Funds Required for Investment Projects Financed by Raised Funds and Replacing Them with an Equal Amount of Raised Funds

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride Tablets

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 and Gecacitinib Hydrochloride Tablets with Chemotherapy Regimen

Announcement on Voluntary Disclosure of Obtaining FDA Approval for the Clinical Trial of ZGGS34 for Injection

Announcement on Voluntary Disclosure of Inclusion of ZG006 for Injection Being Included in the List of Drugs Granted Breakthrough Therapy Designation

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Injectable ZG006

Announcement on Voluntary Disclosure and Signing of Exclusive Marketing Service Agreement for Recombinant Human Thyroid Stimulating Hormone for Injection